Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Naunyn-Schmiedeberg's Archives of Pharmacology

• Publication date

  2004-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00210-004-0957-yPMID 15340774
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AVE 0118, an Antiarrhythmic Drug with a Novel Action Mechanism: Block of Ikur and Ito Potassium Currents in Human Atrial Myocytes

  2006cited by this paper
• “Early” Class III Drugs for the Treatment of Atrial Fibrillation: Efficacy and Atrial Selectivity of AVE0118 in Remodeled Atria of the Goat

  2004cited by this paper
• Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation

  2004influential reference
• Remodeling of cardiomyocyte ion channels in human atrial fibrillation

  2003cited by this paper
• Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.

  2003cited by this paper
• Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.

  2003cited by this paper
• Effects of NIP-141 on K Currents in Human Atrial Myocytes

  2002cited by this paper
• Cellular electrophysiology of atrial fibrillation.

  2002cited by this paper
• Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter.

  2002influential reference
• Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, d,l-sotalol and ibutilide

  2002cited by this paper
• Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes

  2001cited by this paper
• hKChIP2 is a functional modifier of hKv4.3 potassium channels: cloning and expression of a short hKChIP2 splice variant.

  2001cited by this paper
• Differential effects of dofetilide, amiodarone, and class Ic drugs on left and right atrial refractoriness and left atrial vulnerability in pigs

  2001cited by this paper
• Molecular cloning and expression of the novel splice variants of K(+) channel-interacting protein 2.

  2001cited by this paper
• Atrial fibrillation and stroke : concepts and controversies.

  2001cited by this paper
• Modulation of A-type potassium channels by a family of calcium sensors

  2000cited by this paper
• Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study

  2000cited by this paper
• Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.

  1999cited by this paper
• Cloning and expression of the human kv4.3 potassium channel.

  1999cited by this paper
• HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part I: Effects on Cardiomyocytes, Coronary Flow and Pancreatic β-Cells

  1998cited by this paper
• HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: effects on cardiomyocytes, coronary flow and pancreatic beta-cells.

  1998cited by this paper
• Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes.

  1997cited by this paper
• Kainate Binding Proteins Possess Functional Ion Channel Domains

  1997cited by this paper
• A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG

  1997cited by this paper
• Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke.

  1997cited by this paper
• Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current.

  1996cited by this paper
• Myocardial potassium channels: electrophysiological and molecular diversity.

  1996cited by this paper
• Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

  1996cited by this paper
• Differences between outward currents of human atrial and subepicardial ventricular myocytes.

  1996cited by this paper
• Evidence for two components of delayed rectifier K+ current in human ventricular myocytes.

  1996cited by this paper
• Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes.

  1995cited by this paper
• Adenosine triphosphate-dependent K currents activated by metabolic inhibition in rat ventricular myocytes differ from those elicited by the channel opener rilmakalim

  1995cited by this paper
• Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide.

  1994cited by this paper
• Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

  1993cited by this paper
• Delayed rectifier outward current and repolarization in human atrial myocytes.

  1993cited by this paper
• Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.

  1993cited by this paper
• Molecular cloning and characterization of two voltage‐gated K+ channel cDNAs from human ventricle

  1991cited by this paper
• Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure: A Study of 390 Patients

  1991cited by this paper
• Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells.

  1990cited by this paper
• Atrial fibrillation. Is there a safe and highly effective pharmacological treatment?

  1990cited by this paper
• Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation.

  1989cited by this paper
• Epidemiologic features of chronic atrial fibrillation: the Framingham study.

  1982cited by this paper
• Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

  1981cited by this paper

• New drug discovery of cardiac anti-arrhythmic drugs: insights in animal models

  2023cites this paper
• Roles of IK,ACh for perpetuating atrial fibrillation: Effects of atrial-selective K+ channel inhibitor AVE0118 and class I drugs on the persistent atrial fibrillation canine model.

  2022cites this paper
• Simultaneous analyses of hemodynamic and electrophysiological effects of oseltamivir along with its pharmacokinetic profile using the canine paroxysmal atrial fibrillation model.

  2021cites this paper
• Drug screening platform using human induced pluripotent stem cell‐derived atrial cardiomyocytes and optical mapping

  2020cites this paper
• Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent

  2020cites this paper
• Drug Screening Platform Using Human Induced Pluripotent Stem Cell-Derived Atrial Cardiomyocytes and Optical Mapping

  2020cites this paper
• Revealing kinetics and state-dependent binding properties of IKur-targeting drugs that maximize atrial fibrillation selectivity.

  2017cites this paper
• Biophysical modelling of functional impacts of potassium channel mutations on human atrial and ventricular dynamics

  2017cites this paper
• Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin

  2017cites this paper
• Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.

  2016cites this paper
• Patch-Clamp and Voltage-Clamp Techniques

  2015cites this paper
• Novel K+ Channel Targets in Atrial Fibrillation Drug Development—Where Are We?

  2015cites this paper
• Neurogenic Contraction Induced by the Antiarrhythmic Compound, AVE 0118, in Rat Small Mesenteric Arteries

  2014cites this paper
• Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia.

  2014cites this paper
• Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?

  2014cites this paper
• Point of View

  2013cites this paper
• Inhibition of cardiac Kv1.5 and Kv4.3 potassium channels by the class Ia anti-arrhythmic ajmaline: mode of action

  2013cites this paper
• Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs.

  2013cites this paper
• Electrophysiological Characterization and Antiarrhythmic Efficacy of the Mixed Potassium Channel-Blocking Antiarrhythmic Agent AZ13395438 In Vitro and In Vivo

  2013cites this paper
• Experimental studies on new therapeutic approaches in atrial fibrillation

  2013cites this paper
• Atrial-selective Prolongation of Refractory Period With AVE0118 is Due Principally to Inhibition of Sodium Channel Activity

  2012influential citation
• Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention.

  2012cites this paper
• Thiéno- et furo- pyrimidines et pyridines, convenant comme inhibiteurs du canal potassium

  2012cites this paper
• Cardiac ion channels and mechanisms for protection against atrial fibrillation.

  2012cites this paper
• Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea.

  2011cites this paper
• Atrial remodeling and novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation.

  2011cites this paper
• Ion channels and their inhibitors

  2011cites this paper
• Potassium Channel Blockers as Antiarrhythmic Agents

  2011cites this paper
• The pharmaceutical pipeline for atrial fibrillation

  2011cites this paper
• Title Pharmacology of Cardiac Potassium Channels

  2011cites this paper
• Tissue engineering of the human atrium : approaching mechanisms of genesis and control of atrial fibrillation

  2011cites this paper
• Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs.

  2011influential citation
• Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.

  2011cites this paper
• Effects of the novel amiodarone-like compound SAR114646A on cardiac ion channels and ventricular arrhythmias in rats

  2011cites this paper
• Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation

  2010cites this paper
• AZD1305 Exerts Atrial Predominant Electrophysiological Actions and Is Effective in Suppressing Atrial Fibrillation and Preventing Its Reinduction in the Dog

  2010cites this paper
• Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.

  2010cites this paper
• Antiarrhythmic therapy in atrial fibrillation.

  2010cites this paper
• Pharmacology of cardiac potassium channels.

  2010cites this paper
• Inhibition of Small-Conductance Ca2+-Activated K+ Channels Terminates and Protects Against Atrial Fibrillation

  2010cites this paper
• New pharmacological targets and treatments for atrial fibrillation.

  2010cites this paper
• Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation

  2010cites this paper
• Left atrial remodeling in atrial fibrillation - mechanisms, assessment and therapeutic

  2009cites this paper
• Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure

  2009influential citation
• Quantitative Structure–Activity Relationship Models for Predicting Biological Properties, Developed by Combining Structure‐ and Ligand‐Based Approaches: An Application to the Human Ether‐a‐go‐go‐Related Gene Potassium Channel Inhibition

  2009cites this paper
• Voltage-gated potassium channels as therapeutic targets

  2009cites this paper
• Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.

  2009cites this paper
• I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.

  2009cites this paper
• Drug discoveries towards Kv1.5 potassium channel.

  2009cites this paper
• Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties

  2009cites this paper
• Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.

  2009cites this paper
• High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.

  2009cites this paper
• IKur, Ultra‐Rapid Delayed Rectifier Potassium Current: A Therapeutic Target for Atrial Arrhythmias

  2009cites this paper
• Safety Challenges in the Development of Novel Antiarrhythmic Drugs

  2009cites this paper
• IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation

  2009cites this paper
• I Kur /Kv1.5channelblockersforthe treatmentofatrialfibrillation

  2009cites this paper
• Pathology‐specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation

  2008influential citation
• Characterization of Human Cardiac Kv1.5 Inhibition by the Novel Atrial-selective Antiarrhythmic Compound AVE1231

  2008cites this paper
• Can inhibition of IKur promote atrial fibrillation?

  2008cites this paper
• Novel Transient Outward and Ultra-rapid Delayed Rectifier Current Antagonist, AVE0118, Protects Against Ventricular Fibrillation Induced by Myocardial Ischemia

  2008influential citation
• New drugs for atrial fibrillation

  2008cites this paper
• Acacetin, a Natural Flavone, Selectively Inhibits Human Atrial Repolarization Potassium Currents and Prevents Atrial Fibrillation in Dogs

  2008cites this paper
• Inward rectifier potassium currents as a target for atrial fibrillation therapy.

  2008cites this paper
• Kv1.5 Potassium Channel Inhibitors for the Treatment and Prevention of Atrial Fibrillation

  2008cites this paper
• Cellular Electrophysiology and the Substrate for Atrial Fibrillation

  2008cites this paper
• New concepts in understanding and modulating atrial repolarisation in patients with atrial fibrillation

  2008cites this paper
• Pathophysiology and Disease Progression of Atrial Fibrillation: Importance of Achieving and Maintaining Sinus Rhythm

  2008cites this paper
• In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.

  2008influential citation
• New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value

  2008cites this paper
• Atrial-selective approaches for the treatment of atrial fibrillation.

  2008cites this paper
• High-throughput analysis of drug binding interactions for the human cardiac channel , Kv 1

  2008cites this paper
• Pharmacogenetics of drug-induced arrhythmias

  2008cites this paper
• In Vitro and In Vivo Effects of the Atrial Selective Antiarrhythmic Compound AVE1231

  2007cites this paper
• Mechanism of Action of the Antiarrhythmic Agent AZD7009

  2007cites this paper
• Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.

  2007cites this paper
• Pharmacologic targets for atrial fibrillation

  2007cites this paper
• Effect of Atrial Electrical Remodeling on the Efficacy of Antiarrhythmic Drugs: Comparison of Amiodarone with IKr‐ and Ito/IKur‐Blockade In Vivo

  2007cites this paper
• Depolarization and decreased surface expression of K+ channels contribute to NSAID-inhibition of intestinal restitution.

  2007cites this paper
• Herzrhythmusstörungen. Weiterentwicklung der medikamentösen Therapie - eine realistische Perspektive?

  2007cites this paper
• In Vivo Cardiac Electrophysiologic and Antiarrhythmic Effects of an Isoquinoline IKur Blocker, ISQ-1, in Rat, Dog, and Nonhuman Primate

  2007cites this paper
• Strategies for atrial fibrillation therapy: focusing on IKur potassium channel

  2007cites this paper
• Novel anti-arrhythmic agents for the treatment of atrial fibrillation.

  2007cites this paper
• Novel anti-arrhythmic drugs for atrial fibrillation management.

  2007cites this paper
• Rapid communication Blockade of atrial-specific K + -currents increases atrial but not ventricular contractility by enhancing reverse mode Na + /Ca 2+ -exchange

  2007cites this paper
• Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange.

  2007influential citation
• Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.

  2007cites this paper
• Atrial fibrillation: insights from clinical trials and novel treatment options

  2007cites this paper
• Properties of a Time-Dependent Potassium Current in Pig Atrium: Evidence for a Role of Kv1.5 in Repolarization

  2006cites this paper
• Kir3-Based Inward Rectifier Potassium Current: Potential Role in Atrial Tachycardia Remodeling Effects on Atrial Repolarization and Arrhythmias

  2006cites this paper
• AVE 0118, an Antiarrhythmic Drug with a Novel Action Mechanism: Block of Ikur and Ito Potassium Currents in Human Atrial Myocytes

  2006cites this paper
• Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques.

  2006cites this paper
• Novel, Potent inhibitors of human Kv1.5 K channels and IKur

  2006influential citation
• [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

  2006cites this paper
• Binding Site of a Novel Kv1.5 Blocker: A “Foot in the Door” against Atrial Fibrillation

  2006influential citation
• Neue Antiarrhythmika in der Therapie des Vorhofflimmerns

  2006influential citation
• AVE0118, Blocker of the Transient Outward Current (Ito) and Ultrarapid Delayed Rectifier Current (IKur), Fully Restores Atrial Contractility After Cardioversion of Atrial Fibrillation in the Goat

  2006cites this paper
• In Vivo Cardiac Electrophysiologic Effects of a Novel Diphenylphosphine Oxide IKur Blocker, (2-Isopropyl-5-methylcyclohexyl) Diphenylphosphine Oxide, in Rat and Nonhuman Primate

  2006cites this paper
• Molecular mechanisms of cardiac voltage-gated potassium channelopathies.

  2006cites this paper
• [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers].

  2006cites this paper
• Novel, Potent Inhibitors of Human Kv1.5 K+ Channels and Ultrarapidly Activating Delayed Rectifier Potassium Current

  2006cites this paper